Close menu

September 30th, 2021 | 12:20 CEST

BioNTech, Sativa Wellness Group, Aurora Cannabis - For the good of humanity

  • Biotechnology
Photo credits:

One thing has been brought home to humanity since the outbreak of the Corona Pandemic and the rapid development of vaccines - Science and research are essential in identifying health risks and helping people live long and healthy lives. Young companies, in particular, are discovering alternative treatments through their research and using natural products that have centuries of tradition - with great potential.

time to read: 4 minutes | Author: Stefan Feulner

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Aurora Cannabis - Weaker than expected

    After the mega-hype of the cannabis industry in 2019, calm has returned, at least when it comes to the prices of listed companies. But the market still has enormous growth potential and is expected to grow by more than 27% per year between 2021 and 2030, according to market research firm Quince Markets Insights. The current market volume is already around USD 20 billion. Cannabis' health benefits and growing medical applications, in particular, are expected to further accelerate growth.

    One of the stars in the cannabis sky has been the share of Aurora Cannabis. It was trading at a high of over CAD 180. Currently, the Company ekes out a shadowy existence at CAD 8.42, with its market capitalization melting down to EUR 1.15 billion. The figures for the fourth quarter, which ended on June 30 for the Canadians, were accordingly sobering. With revenues of CAD 54.8 million, compared to CAD 72.1 million in the same period last year, the Company fell short of analysts' forecasts, which were based on revenues of CAD 56.8 million. Earnings per share came in at CAD -0.68, down from CAD -16.66 in the fourth quarter of 2020, with analyst firms also expecting a more minor loss of CAD -0.268.

    Despite the weaker-than-expected figures, the stock went up more than 5% after the announcement. However, the initial gains could not be maintained. At the current CAD 8.42, there is a threat of another setback towards CAD 8.0. Therefore the value is only suitable for the watch list.

    Sativa Wellness Group- Extreme turnaround

    Well diversified, more precisely on three independent pillars, stands the Canadian Company Sativa Wellness Group, which also has branches in Great Britain. The Company's stock market value, which is also traded in Frankfurt, is currently at a manageable EUR 17.28 million, significantly lower than the unicorn Aurora Cannabis. Still, the goals of the new management around CEO Mac Howells are no less ambitious.

    In a nutshell, the Sativa Group wants to become one of the leading producers and distributors of high-quality CBD products and CBD services in Europe. CBD stands for cannabidiol, one of the 100 different cannabinoids found in the hemp plant. It has a non-intoxicating effect, unlike THC, and is 100% legal. While people have been using the hemp plant as a medicine for thousands of years, nowadays, the therapeutic properties of CBD are largely confirmed by scientists and doctors and tested all over the world. According to the CBD Industry Growth Report, the global CBD market had an estimated value of USD 4.6 billion in 2018, and this figure has already doubled by 2020.

    Sativa Wellness Group's three separate segments include testing services for clinics, as well as direct-to-consumer and direct-to-business services, in addition to manufacturing a range of CBD products on a gold-standard basis for consumers under the Goodbody Botanicals brand. This business is managed under Goodbody Wellness. With PhytoVista, Sativa also owns one of the top 3 CBD and hemp testing laboratories in Europe.

    Following the realignment of the management team and the strict demarcation of the divisions, the Canadians were already able to post record sales in the first quarter. In addition, the Goodbody Botanicals trading division has been consistently in the black since the beginning of the year after years of losses. The figures for the second quarter now clearly show the success of the restructuring measures and point to the enormous potential for the future. Revenue increased by 828% to CAD 6 million compared to the same quarter last year. Gross profit increased 804% to CAD 3.3 million in the second quarter of 2021 compared to the same quarter in 2020, with a gross margin of 55%. Thus, the first net profit in history was brought in with a plus of CAD 79,000; in the previous year, the result still amounted to a net loss of CAD 2.4 million.

    In addition to the numbers, other operational milestones were achieved. PhytoVista Laboratories received ISO/IEC (International Electrotechnical Commission) accreditation. Goodbody Botanicals was listed on the UK government website to offer two- and eight-day quarantine testing for travelers returning to the UK, representing a significant opportunity for Sativa's COVID testing clinics. The trend is absolutely in the right direction for Sativa Wellness Group. Speculative investors should watch the stock more closely.

    BioNTech - Strongly punished

    From a fundamental perspective, nothing negative has happened in recent days at the Mainz-based vaccine manufacturer BioNTech. Together with its US partner Pfizer, the Company plans to apply to the US Food and Drug Administration (FDA) for emergency approval of its COVID-19 vaccine for children aged 5 to 11 in the coming weeks. In addition, approval for annual booster vaccines remains on the table, which should provide BioNTech with recurring revenue.

    However, looking at the chart-technical picture, not only of the Mainz-based Company but also that of Pfizer or Moderna, extreme caution is called for. With the break of the striking support zone at EUR 325, a strong sell signal was generated, whereby the share already meets the next important mark at EUR 275 after the strong sell-off.

    Should this also be torn with high volume, a further setback threatens, initially in the area around EUR 250. In terms of valuation, a correction is more than healthy. A stock market value of USD 68.36 billion seems very ambitious. Investors should first wait for things to calm down.

    Research is breaking new ground and looking for alternative treatments. Although the cannabis market is predicted to experience extreme growth, stocks like Aurora Cannabis continue to consolidate at low levels. Sativa Wellness Group is interesting in the long term due to a successful turnaround. BioNTech is caught in the middle of a correction and is only suitable for the Watch List.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.